Top 5 Stocks to Buy Now
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free REVBW Stock Alerts

Revelation Biosciences (REVBW) Competitors

Revelation Biosciences logo
$0.0076 0.00 (-17.32%)
Closing price 06/18/2026 03:55 PM Eastern
Extended Trading
$0.01 +0.00 (+19.37%)
As of 06/18/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

REVBW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Revelation Biosciences stock or one of its competitors? MarketBeat compares Revelation Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revelation Biosciences include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Revelation Biosciences compare to Ainos?

Revelation Biosciences (NASDAQ:REVBW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A N/A N/A
Ainos N/A N/A N/A

In the previous week, Revelation Biosciences' average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company Overall Sentiment
Revelation Biosciences Neutral
Ainos Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

Summary

Ainos beats Revelation Biosciences on 1 of the 1 factors compared between the two stocks.

How does Revelation Biosciences compare to Alvotech?

Revelation Biosciences (NASDAQ:REVBW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, Revelation Biosciences' average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score.

Company Overall Sentiment
Revelation Biosciences Neutral
Alvotech Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

Summary

Alvotech beats Revelation Biosciences on 1 of the 1 factors compared between the two stocks.

How does Revelation Biosciences compare to Aravive?

Revelation Biosciences (NASDAQ:REVBW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Revelation Biosciences' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Revelation Biosciences Neutral
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A N/A N/A
Aravive N/A N/A N/A

Summary

Aravive beats Revelation Biosciences on 2 of the 2 factors compared between the two stocks.

How does Revelation Biosciences compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Revelation Biosciences (NASDAQ:REVBW) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Revelation Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Revelation BiosciencesN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Revelation Biosciences N/A N/A N/A

Summary

Atlantic Coastal Acquisition Corp. II and Revelation Biosciences tied by winning 0 of the 0 factors compared between the two stocks.

How does Revelation Biosciences compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Revelation Biosciences (NASDAQ:REVBW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Biofrontera's average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
Biofrontera Neutral
Revelation Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Revelation BiosciencesN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Revelation Biosciences N/A N/A N/A

Summary

Biofrontera beats Revelation Biosciences on 1 of the 1 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVBW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVBW vs. The Competition

Export
MetricRevelation BiosciencesBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$381.56M$6.43B$12.59B
Dividend YieldN/A3.86%2.68%5.81%
P/E RatioN/A3.1224.7524.42
Price / SalesN/A6,861.77529.99108.89
Price / CashN/A13.1345.0755.09
Price / BookN/A92.2610.806.58
Net IncomeN/A-$96.07M$3.57B$337.17M
7 Day PerformanceN/A0.88%0.72%0.83%
1 Month PerformanceN/A-0.66%0.41%2.25%
1 Year PerformanceN/A54.58%29.34%36.14%

Revelation Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVBW
Revelation Biosciences
N/A$0.01
-17.3%		N/A-35.8%$0.00N/AN/A10
AIMDW
Ainos
N/A$0.08
-37.5%		N/A-48.8%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.24
+19.0%		N/AN/A$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:REVBW) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel